Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care

Weranja K.B. Ranasinghe; Chad A. Reichard; Brian F. Chapin

doi:10.1016/j.eururo.2019.06.014

Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care

Weranja K.B. Ranasinghe, Chad A. Reichard, Brian F. Chapin

Urology

Research output: Contribution to journal › Editorial › peer-review

1 Scopus citations

Abstract

Retrospective studies in selected patients have demonstrated a survival benefit with prostatectomy or radiotherapy (RT) of the primary tumor in metastatic hormone-sensitive prostate cancer (mHSPC). However, there is currently not enough evidence to recommend RT to the primary tumor as the standard of care for patients treated with androgen deprivation therapy plus abiraterone or docetaxel for low-volume mHSPC.

Original language	English (US)
Pages (from-to)	543-545
Number of pages	3
Journal	European urology
Volume	76
Issue number	5
DOIs	https://doi.org/10.1016/j.eururo.2019.06.014
State	Published - Nov 2019

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2019.06.014

Cite this

@article{af30983be5904350bd7cf76f46d3ea27,

title = "Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care",

abstract = "Retrospective studies in selected patients have demonstrated a survival benefit with prostatectomy or radiotherapy (RT) of the primary tumor in metastatic hormone-sensitive prostate cancer (mHSPC). However, there is currently not enough evidence to recommend RT to the primary tumor as the standard of care for patients treated with androgen deprivation therapy plus abiraterone or docetaxel for low-volume mHSPC.",

author = "Ranasinghe, {Weranja K.B.} and Reichard, {Chad A.} and Chapin, {Brian F.}",

note = "Publisher Copyright: {\textcopyright} 2019",

year = "2019",

month = nov,

doi = "10.1016/j.eururo.2019.06.014",

language = "English (US)",

volume = "76",

pages = "543--545",

journal = "European urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "5",

}

TY - JOUR

T1 - Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer

T2 - Not Yet Ready for Prime Time as the Standard of Care

AU - Ranasinghe, Weranja K.B.

AU - Reichard, Chad A.

AU - Chapin, Brian F.

PY - 2019/11

Y1 - 2019/11

N2 - Retrospective studies in selected patients have demonstrated a survival benefit with prostatectomy or radiotherapy (RT) of the primary tumor in metastatic hormone-sensitive prostate cancer (mHSPC). However, there is currently not enough evidence to recommend RT to the primary tumor as the standard of care for patients treated with androgen deprivation therapy plus abiraterone or docetaxel for low-volume mHSPC.

AB - Retrospective studies in selected patients have demonstrated a survival benefit with prostatectomy or radiotherapy (RT) of the primary tumor in metastatic hormone-sensitive prostate cancer (mHSPC). However, there is currently not enough evidence to recommend RT to the primary tumor as the standard of care for patients treated with androgen deprivation therapy plus abiraterone or docetaxel for low-volume mHSPC.

UR - http://www.scopus.com/inward/record.url?scp=85067691710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067691710&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2019.06.014

DO - 10.1016/j.eururo.2019.06.014

M3 - Editorial

C2 - 31248604

AN - SCOPUS:85067691710

SN - 0302-2838

VL - 76

SP - 543

EP - 545

JO - European urology

JF - European urology

IS - 5

ER -

Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this